Adovate
Robert D. Thompson is currently serving as the Vice President of Chemistry at a pharmaceutical development and chemistry company focused on inventing and developing adenosine analogs for various diseases. Prior to their current role, Robert held executive positions at several other pharmaceutical companies where Robert D. contributed to the research and development of adenosine-related compounds. With a PhD in Organic Chemistry, Robert brings over 30 years of experience in the field.
This person is not in any teams
Adovate
Adovate develops novel drugs that target adenosine receptors involved in major diseases. These drug candidates have been created using our next-generation adenosine drug development platform, which enable design of patented compounds with favorable physiochemical characteristics and distribution kinetics that historically limited drugs acting against the adenosine receptors.